Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

12 May 2015

Abstract excerpt

The DNA damage response kinase ATR may be a useful cancer therapeutic target. ATR inhibition synergizes with loss of ERCC1, ATM, XRCC1 and DNA damaging chemotherapy agents. Clinical trials have begun using ATR inhibitors in combination with cisplatin. Here we report the first synthetic lethality screen with a combination treatment of an ATR inhibitor (ATRi) and cisplatin. Combination treatment with ATRi/cisplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25965342
DOI: 10.1371/journal.pone.0125482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin TreatmentsPMID 25965342Read ↗

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatmentSemantic proximity Read ↗

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?Semantic proximity Read ↗

Drugging the Cancers Addicted to DNA RepairSemantic proximity Read ↗

DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directionsSemantic proximity Read ↗

Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer CellsSemantic proximity Read ↗

Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination StrategiesSemantic proximity Read ↗

ATM and ATR as therapeutic targets in cancerSemantic proximity Read ↗

Targeting DNA damage repair precision medicine strategies in cancerSemantic proximity Read ↗

DNA Damage Repair Deficiency and Synthetic Lethality for Cancer Treatment.Semantic proximity Read ↗

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.Semantic proximity Read ↗

Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeuticsSemantic proximity Read ↗

DNA Damage Response Pathways in Tumor Suppression and Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.